After gathering enough Nektar, Lilly hands back rights to immunology med post-lupus fail

After gathering enough Nektar, Lilly hands back rights to immunology med post-lupus fail

Source: 
Fierce Biotech
snippet: 

The writing was on the wall for Nektar Therapeutics and Eli Lilly’s rezpeg collaboration, but, now, the Big Pharma is etching it in permanent marker. Rights for the T regulatory cell stimulator treatment are now headed back to the biotech.